Regeneron Pharmaceuticals (REGN) is back in focus after Japan approved Dupixent as the first targeted treatment for adults ...
Considerable on MSN
Apogee signals best-case outlook for Dupixent rival
Apogee Therapeutics signaled a “best case scenario” on Monday for its experimental eczema treatment, ...
Sanofi said a jump in sales of its blockbuster Dupixent drug and robust pharmaceutical launches drove higher revenue and adjusted earnings for the third quarter, as the company continues in talks with ...
Investor's Business Daily on MSN
How Apogee, up almost 20%, plans to take on rival Regeneron's eczema drug
Apogee Therapeutics reported a "best case scenario" Monday for its potential rival to eczema drug, Dupixent.
Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...
A multibagger stock is one that has doubled your money or more. Peter Lynch, the highly respected investment manager who ran the Magellan Fund for 14 years, coined the term in his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results